With regard to its innovative antibacterial silver coating technology,aapwas able to successfully resume recruitment in the ongoing human clinical trial with an adapted study design and achieve a significant acceleration in patient recruitment after only a short time with the new study protocol.
Currently,aapexpects patient recruitment to be completed in 12 to 18 months involving 12 to 14 clinical trial centers. Cure trials that have been very successful so far makeaapoptimistic that this result will also be reflected in the clinical trial.
With its groundbreaking surface modification technology, in which elemental silver is incorporated into the titanium surface in an extremely low but highly effective concentration,aapis aiming for a unique selling proposition that effectively counters increasing antibiotic resistance in medicine and has the potential to become the gold standard in traumatology. Depending on the human clinical trial and the regulatory authorities,aapexpects the first market launch of the new technology in 3 years.
In addition to the human clinical trial, the Company will increasingly start to participate in events of the medical scientific societies, nationally and internationally, in the coming months and thus prepare the first steps of the market introduction phase to make the product better known in the market.
-------------------------------------------------------
aapImplantate AG (ISIN DE0005066609) - General Standard/Regulated Market - All German Stock Exchanges -
AboutaapImplantate AG
aapImplantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the IP-protected portfolio includes a wide range of cannulated screws. In addition,aapImplantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany,aapImplantate AG sells its products directly to hospitals, purchasing groups and group clinics, while at international level it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies onahybrid sales strategy through its subsidiaryaapImplants Inc. This involves sales both via distribution agents and as part of partnerships with global orthopedic companies. TheaapImplantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.
The figures presented in this press release may be subject to technical rounding differences which do not affect the overall presentation.
Forward-looking statements
This release may contain forward-looking statements based on current expectations, beliefs and projections of the Management Board and currently available information. The forward-looking statements are not guarantees of future performance or results. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed inaap'spublic reports. Forward-looking statements therefore speak only as of the date they are made. We assume no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.
Contact:
aapImplantate AG; Marek Hahn; Member of the Management Board, CFO; Lorenzweg 5; 12099 Berlin
Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; E-Mail:m.hahn@aap.de
Attachments
Disclaimer
aap Implantate AG published this content on 20 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2023 07:31:29 UTC.